Related Experiment Video
Updated: Mar 13, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[Treatment of Advanced Squamous Cell Lung Cancer]
Yixiang Zhu1, Puyuan Xing1, Junling Li1
1National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract:
Lung cancer is the deadliest cancer in the worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung tumor diagnoses. Squamous cell lung cancer (SQCLC) is a common pathological type, almost 20%-30% of NSCLC. Surgery, chemotherapy, and molecular targeted therapies are the mainstay of treatment for patients with SQCLC. But most patients are diagnosed at advanced stage so that they miss the chance of operation. While noteworthy outcomes have improved with adenocarcinoma of lung with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a therapeutic plateau for advanced squamous cell lung cancer patients are still not solved. EGFR-TKIs are unsuitable for or mostly ineffective in advanced SQCLC. Patients with advanced SQCLC ramain treated with platinum based chemotherapy. This reciew systematicly describe the treatment of squamous cell carcinoma of the lung.
Insights
Squamous cell lung cancer (SQCLC) treatment remains challenging, with limited options beyond chemotherapy for advanced stages. This review systematically explores current therapeutic strategies for SQCLC.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Lung cancer is a leading cause of cancer death globally.
- Non-small cell lung cancer (NSCLC) comprises 85% of lung cancer diagnoses.
- Squamous cell lung cancer (SQCLC), a subtype of NSCLC, accounts for 20-30% of cases.
Purpose of the Study:
- To systematically review the current treatment landscape for squamous cell lung cancer.
- To highlight the limitations of existing therapies, particularly for advanced stages.
- To provide an overview of treatment options for SQCLC patients.
Main Methods:
- Systematic review of literature on squamous cell lung cancer treatments.
- Analysis of current therapeutic mainstays including surgery, chemotherapy, and targeted therapies.
- Evaluation of the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in SQCLC.
Main Results:
- Advanced stage diagnosis often precludes surgical intervention for SQCLC.
- EGFR-TKIs, successful in lung adenocarcinoma, show limited efficacy in advanced SQCLC.
- Platinum-based chemotherapy remains the primary treatment for advanced SQCLC.
Conclusions:
- There is a significant unmet need for effective treatments for advanced squamous cell lung cancer.
- Current therapeutic strategies for SQCLC are limited, with chemotherapy being the standard.
- Further research is crucial to develop novel and effective therapies for SQCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Tumor Immunotherapy